Cesarini ValerianaDocente a contratto esterno-Art.23 Legge 240/10
Scientific Disciplinary Sector Code
||ANATOMIA UMANA (BIO/16)
||Saint Camillus International University of Health Sciences
Facoltà dipartimentale di Medicina
Reception timesMercoledi dalle ore 11:00 alle ore 12:00.
Wednesday 11:00-12:00 am.
Name: Valeriana Cesarini
-22/12/2015: PhD in Biotechnology and Translational Medicine, Department of Anatomy, University of Tor Vergata, Rome, Italy. Dissertation: “Role of PDE5 in tumor invasion and DNA repair in Glioblastoma Multiforme”; “Role of Sox2 in BRAFV600E and PTEN null driven melanoma.” Advisor: Prof. Susanna Dolci.
- 13/10/2011: 2nd level Degree in Medical Biotechnologies (two-years course), highest honors, Catholic University of Rome, Italy. Dissertation: “Prognostic relevance of EBV-positivity and CD68 in Hodgkin's lymphoma.” Advisor: Prof. Luigi Maria Larocca.
- 01/04/2009: 1st level Degree in Sanitary Biotechnologies (three-years course), Catholic University of Rome, Italy. Dissertation: “Prognostic relevance of K-RAS mutations in sporadic colorectal carcinoma” Advisor: Prof Luigi Maria Larocca.
- January 2016-up to now: Postdoctoral fellow, Department of Oncoematology, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
The research activity is primary focused on A to I RNA editing and in particular on investigation of the role of Adar2 enzyme as an oncosuppressor in Glioblastoma Multiforme using a mouse model.
- November 2012 – December 2015: PhD in Biotechnology and Translational Medicine, Department of Anatomy, University of Tor Vergata, Rome, Italy. The research activity was focused on the role of Phosphodiesterase type 5 in regulation of Glioblastoma Multiforme invasiveness and on the Role of Sox2 in the development of BRafV600E and Pten null driven melanoma.
- December 2011 – November 2012: Research fellowship at Catholic University of the Sacred Heart, Rome, Department of Neurosurgery. The research activity was focused on primary Glioblastoma Cancer stem cells characterization.
- December 2009 – November 2011: Undergraduate student at Catholic University of the Sacred Heart, Rome, Department of Molecular Pathology. The research activity was focused on the role of EBV-positivity and CD68 expression in Hodgkin lymphomas.
- December 2007 – November 2009: Undergraduate student Catholic University of Rome, Department of Molecular Pathology. The research activity was focused on prognostic role of K-RAS mutations in colorectal cancer.
1) Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. D A Silvestris; E Picardi; V Cesarini; B Fosso; N Mangraviti; L Massimi; M Martini; G Pesole; F Locatelli; A Gallo. Genome Biology 2019 Feb.
2) ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion.
V Cesarini, D A Silvestris, V Tassinari, S Tomaselli, S Alon, E Eisenberg, F Locatelli and Angela Gallo. Nucleic Acids Res. 2018 Feb 28;46(4):2045-2059.
3) Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo. Cesarini V, Guida E, Todaro F, Di Agostino S, Tassinari V, Nicolis S, Favaro R, Caporali S, Lacal PM, Botti E, Costanzo A, Rossi P, Jannini EA, Dolci S. Oncogene. 2017 Aug;36(31):4508-4515.
4) Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Cesarini V, Martini M, Vitiani LR, Gravina GL, Di Agostino S, Graziani G, D'Alessandris QG, Pallini R, Larocca LM, Rossi P, Jannini EA, Dolci S. Oncotarget. 2017 Feb 21;8(8):13223-13239.
5)Fgf9 inhibition of meiotic differentiation in spermatogonia is mediated by Erk-dependent activation of Nodal-Smad2/3 signaling and is antagonized by Kit Ligand.
Tassinari V, Campolo F, Cesarini V, Todaro F, Dolci S, Rossi P. Cell Death Dis. 2015 Mar 12;6:e1688.
6)Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells.
Carosa E, Castri A, Forcella C, Sebastiani G, Di Sante S, Gravina GL, Ronchi P,Cesarini V, Dolci S, Di Stasi S, Lenzi A, Jannini EA. J Sex Med. 2014 Jul;11(7):1675-84.
7)Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis.
M. Martini, T. Cenci, G. Q. D’Alessandris, V. Cesarini, A. Cocomazzi, L. Ricci-Vitiani, R. De Maria, Roberto Pallini, L. M. Larocca. Cancer. 2013 Mar 1;119(5):1004-12.
8)The viral load of Epstein-Barr virus (EBV)-DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma.
S. Hohaus, R. Santangelo, M. Giachelia, B. Vannata, G. Massini, A. Cuccaro, M. Martini, V. Cesarini, T. Cenci, F. D’Alò, M.T. Voso, G. Fadda, G. Leone, L. M. Larocca. Clin Cancer Res. 2011; 17:2885-92
COMMUNICATION in NATIONAL/INTERNATIONAL CONGRESSES
1) AACR Annual Meeting 2017. Walter E. Washington Convention Center, Washington, D.C., USA
Deciphering Inosinome in Glioblastoma versus normal cortex and astrocytes
A. D. Silvestris, E. Picardi, V. Cesarini, V. Tassinari, N. Mangraviti, G. Pesole, F. Locatelli, and A. Gallo.
2)Society for Melanoma Research 2015 International Congress, San Francisco, California, November 18-21, 2015
Role of Sox2 in the development of BRafV600E and Pten null driven melanoma
V.Cesarini, S Dolci
3) GBM 2015 Conference, II International Symposium on Clinical and Basic Investigation, Toledo, Spain 9-12 September 2015
Phosphodiesterase type 5 regulates glioblastoma invasiveness
V. Cesarini, S. Dolci and E.A. Jannini
4) 38° Congresso Nazionale Societa’ Italiana di Endocrinologia, Taormina, ME, 27-30 maggio 2015
Phosphodiesterase type 5 transcriptional regulation in myometrial cells
V. Cesarini, Martini M, Pallini R Ricci Vitiani, L. M. Larocca , E.A. Jannini and S. Dolci